The generic name for the Mannitol Ring is Levonorgestrel Intrauterine Sustained Release System. Patients with endometrial cancer should not be placed with the Levonorgestrel Intrauterine Sustained-Release System.
Endometrial cancer is a malignant tumor that develops in the lining of the uterus. Once diagnosed, surgery is the treatment of choice. In addition, according to the patient’s condition analysis, clinical symptoms, combined with radiotherapy, endocrine therapy to control the disease. Levonorgestrel intrauterine extended-release system has no therapeutic effect on endometrial cancer.
The placement of levonorgestrel intrauterine extended-release system may also lead to increased bleeding, which is a side effect of levonorgestrel intrauterine extended-release system, especially in the first three months after the placement, it is easier to have problems such as increased menstrual flow.
Patients with endometrial cancer should go to the hospital in time to improve the relevant examination and be actively treated under the guidance of professional doctors.